Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neuroinflammation in Patients With OCD
Sponsor: New York State Psychiatric Institute
Summary
The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.
Official title: A Precision Medicine Approach to OCD Treatment: Targeting Neuroinflammation
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2021-04-01
Completion Date
2026-10-28
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Interventions
Celecoxib
Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
Locations (1)
New York State Psychiatric Institute
New York, New York, United States